71. The antibody of claim 70, wherein said antibody is a monoclonal antibody.

72. The antibody of claim 70, wherein the antibody is a humanized antibody.

73. A composition comprising the polypeptide of claim 62 and a pharmaceutically-acceptable carrier.

74. A composition comprising the antibody of claim 70 and a pharmaceutically-acceptable carrier.

75. A composition comprising the antibody of claim 71 and a pharmaceutically-acceptable carrier.

76. A composition comprising the antibody of claim 72 and a pharmaceutically-acceptable carrier. --

REMARKS

Upon entry of the present amendment, claims 62-76 are pending in the application. New claims 62-69 and 73 are drawn to proteins, the subject matter of the elected invention of Group IV. Claims 70-72 and 74-76 are drawn to antibodies, the subject matter of Group V.

Support for new claims 62-76 appears in claims 26-30, 31-33 and 44-47 and in the specification, *e.g.* pages 24-25 and page 26, second paragraph. Thus, these amendments add no new matter.

CONCLUSION

On the basis of the foregoing amendments, Applicants respectfully submit that the pending claims are in condition for allowance. If there are any questions regarding these amendments and remarks, the Examiner is encouraged to contact either of the undersigned at the telephone number provided below.

Applicants:. Conrad and Mach U.S.S.N. 09/490,700

A petition for extension of time accompanies this response. Although Applicants believe that no additional fees are due in connection with this submission, the Commissioner is hereby authorized to charge any additional fee due with this submission, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 23135-502 (NOV-2).

Dated: September 20, 2001

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529

Kristin E. Konzak, Reg. No. 44,848

Attorney/Agent for Applicant

MINTZ, LEVIN, COHN, FERRIS

GLOVSKY and POPEO, P.C.

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000

TRA 1538448v1